Exelixis, Inc. (NASDAQ:EXEL) Director Sue Gail Eckhardt Sells 18,838 Shares

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Sue Gail Eckhardt sold 18,838 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $42.74, for a total value of $805,136.12. Following the completion of the transaction, the director now directly owns 21,380 shares in the company, valued at $913,781.20. The trade was a 46.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis Price Performance

EXEL stock traded up $0.66 during trading hours on Friday, reaching $43.03. 2,335,750 shares of the stock were exchanged, compared to its average volume of 2,331,064. The firm's 50-day moving average is $38.90 and its 200-day moving average is $36.58. Exelixis, Inc. has a 12 month low of $21.36 and a 12 month high of $48.85. The company has a market cap of $11.73 billion, a price-to-earnings ratio of 24.31, a PEG ratio of 1.13 and a beta of 0.28.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on EXEL shares. Bank of America upped their price target on shares of Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a research report on Thursday. JMP Securities reaffirmed a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a research note on Thursday, April 17th. Morgan Stanley reissued an "overweight" rating and issued a $47.00 target price (up previously from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. Royal Bank of Canada restated an "outperform" rating and set a $40.00 target price on shares of Exelixis in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $39.35.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Frank Rimerman Advisors LLC boosted its position in Exelixis by 4.7% during the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company's stock worth $234,000 after acquiring an additional 285 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Exelixis by 6.1% during the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company's stock worth $195,000 after buying an additional 307 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in Exelixis by 1.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company's stock worth $573,000 after buying an additional 317 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company's stock worth $235,000 after buying an additional 330 shares during the last quarter. Finally, Rathbones Group PLC grew its holdings in shares of Exelixis by 5.3% in the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company's stock valued at $253,000 after acquiring an additional 347 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.